Status:
COMPLETED
Antithrombotics' Therapeutic Optimization in Hospitalized Patients Using Physiologically- and Population-based Pharmacokinetic Modeling
Lead Sponsor:
University Hospital, Geneva
Conditions:
Cardiovascular Diseases
Eligibility:
All Genders
18+ years
Brief Summary
The main goal of the OptimAT study main goal is to validate a PBPK model for 3 direct oral anticoagulants (rivaroxaban, apixaban, dabigatran) and 3 P2Y12 inhibitors (clopidogrel, ticagrelor, prasugrel...
Detailed Description
Patients treated with antithrombotics are at risk of both severe ischemic and bleeding events. However, current clinical scores are insufficiently discriminant to predict the most favorable drug and d...
Eligibility Criteria
Inclusion
- Hospitalized patients at any of the Geneva University Hospitals 18 yo and older
- Treated with DOAC (dabigatran, rivaroxaban, apixaban) or/and P2Y12 (clopidogrel, ticragrelor et prasugel) at the time of study blood sampling
- Understanding of French language and able to give an inform consent.
Exclusion
- Patients with a reduced life span (\<6 mois)
- Exclusion criteria during follow up
- Change in dosage or cessation of the DOAC or P2Y12 taken by the participant follow up data will be censored at the time of change.
Key Trial Info
Start Date :
January 14 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 31 2024
Estimated Enrollment :
444 Patients enrolled
Trial Details
Trial ID
NCT03477331
Start Date
January 14 2018
End Date
January 31 2024
Last Update
April 10 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hopitaux universitaires de Genève, 4 rue Gabrielle-Perret-Gentil
Geneva, Canton of Geneva, Switzerland, 1205